In silico Clinical Trials with Virtual Populations Help Accelerate Access to New Drugs

Life Sciences, Clinical Trials, Pharmaceutical, Drug Discovery & Development,
  • Thursday, May 05, 2022

In silico modeling enhances clinical trials. Unlike regular clinical trials, in silico clinical trials enable researchers to explore an almost unlimited number of hypotheses.

Mechanistic modeling encompasses more available knowledge than other in silico approaches. It can be useful even when data is limited. Mechanistic models create virtual populations that allow researchers to simulate both individual- and population-level effects. It captures differences between individuals, as well as intra-individual variability — changes within the same individual that may occur over time. In silico approaches are critical as medicines become more personalized and conventional trials become more challenging, both practically and ethically. This explains regulators’ strong interest in model-informed drug development.

Join this webinar to learn more about the advantages of adopting in silico clinical trials with mechanistic models for drug development.


Emmanuel Pham, Novadiscovery

Emmanuel Pham, VP Science & Customer Experience Europe, Novadiscovery

Emmanuel has more than 20 years of pharmaceutical industry and academic experience.

He is in charge of strengthening NOVA’s relationships with pharmaceutical companies to understand their specific requirements for incorporating in silico technology into existing clinical development programs with a view to streamlining the development process through smaller, more effective clinical trials. He also works with regulatory authorities to develop protocols to aid pharmaceutical companies in including clinical simulation data into regulatory dossiers for new drug applications.

Message Presenter

Who Should Attend?

  • Biotech/Pharma
  • Academics
  • Patient advocacy groups
  • Healthcare providers

What You Will Learn

  • The advantages of in silico clinical trials based on mechanistic modeling
  • How mechanistic modeling differs from (but can complement) data-driven and artificial intelligence (AI) approaches
  • Why embracing modeling has become urgent
  • Why the US Food and Drug Administration (FDA) and the European Medicines Agency (EMA) are interested

Xtalks Partner


Nova has built the world’s first collaborative clinical trial simulation platform, JINKOⓇ, for pharma companies to bring innovative medicines to patients faster and with greater confidence.

You Must Login To Register for this Free Webinar

Already have an account? LOGIN HERE. If you don’t have an account you need to create a free account.

Create Account